目的 探討殼脂膠囊聯(lián)合吡格列酮治療非酒精性脂肪肝的臨床療效。方法 選取2015年5月-2016年5月在廣州市花都區(qū)人民醫(yī)院接受治療的非酒精性脂肪肝病患者86例，根據(jù)治療方案的差別分為對(duì)照組（43例）和治療組（43例）。對(duì)照組口服鹽酸吡格列酮片，1片/次，1次/d。治療組在對(duì)照組的基礎(chǔ)上口服殼脂膠囊，5粒/次，3次/d。兩組患者均連續(xù)治療2個(gè)月。評(píng)價(jià)兩組患者臨床效果，同時(shí)比較兩組治療前后血脂、肝功能、血清炎性因子和氧化應(yīng)激水平變化。結(jié)果 治療后，對(duì)照組的總有效率為81.40%，顯著低于治療組的95.35%，兩組總有效率比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者三酰甘油（TG）、總膽固醇（TC）、低密度脂蛋白膽固醇（LDL-C）、丙氨酸氨基轉(zhuǎn)移酶（ALT）、天門(mén)冬氨酸氨基轉(zhuǎn)移酶（AST）和γ-谷氨酰轉(zhuǎn)移酶（γ-GT）均比同組治療前顯著降低，而高密度脂蛋白膽固醇（HDL-C）水平均明顯升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組上述指標(biāo)改善程度優(yōu)于對(duì)照組（P<0.05）。治療后兩組患者血清超敏C-反應(yīng)蛋白（hs-CRP）、腫瘤壞死因子-α（TNF-α）、白細(xì)胞介素-6（IL-6）均較同組治療前明顯降低（P<0.05）；且治療組上述指標(biāo)降低的更顯著（P<0.05）。治療后兩組血清丙二醛（MDA）水平均降低，超氧化物歧化酶（SOD）活性升高，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組上述指標(biāo)改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 殼脂膠囊聯(lián)合吡格列酮治療非酒精性脂肪肝病效果顯著，可明顯改善患者肝功能，降低血脂、炎性反應(yīng)及氧化應(yīng)激水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Kezhi Capsules combined with pioglitazone in treatment of non-alcoholic fatty liver. Methods Patients (86 cases) with non-alcoholic fatty liver in Huadu District People's Hospital of Guangzhou from May 2015 to May 2016 were divided into control (43 cases) and treatment (43 cases) groups according to different treatments. Patients in the control group were po administered with Pioglitazone Hydrochloride Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Kezhi Capsules on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and blood lipid, liver function, serum inflammatory factors, and oxidative stress levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.40%, which was significantly lower than 95.35% in the treatment group, and there were differences between two groups (P<0.05). After treatment, TG, TC, LDL-C, ALT, AST, and γ-GT in two groups was significantly decreased, but HDL-C level was increased, the difference was statistically significant in the same group (P<0.05). And these indicators in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the serum hs-CRP, TNF-α, and IL-6 in two groups were significantly decreased (P<0.05). And these indexes in the treatment group were decreased with significant difference between two groups (P<0.05). Compared with those before treatment, MDA level in two groups after treatment was significantly decreased, but SOD was increased, and the difference was statistically significant in the same group (P<0.05). And the improvement of these indicators in the treatment group was better than that in the control group, with significant difference between two groups (P<0.05). Conclusion Kezhi Capsules combined with pioglitazone has a significant effect in treatment of non-alcoholic fatty liver, can significantly improve the liver function and reduce blood lipid, inflammatory reaction and oxidative stress level, which has a certain clinical application value.